CYP19A1 and obesity disorder: Univariable regression analysis showed that age more than 40 years, living in an urban area, menarche younger than 14 years old, breastfeeding practice, the preexistence of obesity, and receiving adjuvant hormonal therapy particularly aromatase inhibitors were associated with an increased risk of developing multiple metabolic comorbidities (Table 8).